Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium

Experimental Physiology

Volumn 93, Issue 1, 2008, Pages 141-147

  Mitchell, Jane A ^a   Ali, Ferhana ^a   Bailey, Lucy ^a   Moreno, Laura ^a   Harrington, Louise S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; CYCLIC GMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; GUANYLATE CYCLASE; HORMONE; ICOSANOID; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PROSTACYCLIN; PROSTAGLANDIN E2; VASOACTIVE AGENT;

BLOOD VESSEL; CONFERENCE PAPER; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; INFLAMMATION; SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOSIS; VASODILATATION;

EID: 37349000934     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.038588     Document Type: Conference Paper

References (53)

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N & Metters KM (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483, 285 293.
2. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW & Phipps RP (2004). Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104, 1361 1368.
3. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD & Mitchell JA (2006a). Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ. FASEB J 20, 326 328.
4. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD & Mitchell JA (2006b). Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 34, 242 246.
5. 2 Online, abstract 043P.
6. 2 Online, abstract 032P.
7. Beny JL, Brunet P & Huggel H (1987). Interaction of bradykinin and des-Arg9-bradykinin with isolated pig coronary arteries: mechanical and electrophysiological events. Regul Pept 17, 181 190.
8. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG & Moller DE (1999). Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J Biol Chem 274, 6718 6725.
9. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM & Abramovitz M (1994). Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 269, 12173 12178.
10. Botting R & Vane JR (1989). Mediators and the anti-thrombotic properties of the vascular endothelium. Ann Med 21, 31 38.
11. Breyer RM, Bagdassarian CK, Myers SA & Breyer MD (2001). Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41, 661 690.
12. Chen G, Suzuki H & Weston AH (1988). Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95, 1165 1174.
13. de Nucci G, Gryglewski RJ, Warner TD & Vane JR (1988). Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A 85, 2334 2338.
14. Feletou M & Vanhoutte PM (2006). Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 26, 1215 1225.
15. Forman BM, Chen J & Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci U S A 94, 4312 4317.
16. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A & Sessa WC (1998). Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392, 821 824.
17. Ghosh DK & Salerno JC (2003). Nitric oxide synthases: domain structure and alignment in enzyme function and control. Front Biosci 8, d193 d209.
18. Hanafy KA, Krumenacker JS & Murad F (2001). NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit 7, 801 819.
19. Harrington L, Carrier MJ, Gallagher N, Gilroy D, Garland CJ & Mitchell JA (2007). Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol 293, H1682 1688.
20. Johann AM, Barra V, Kuhn AM, Weigert A, von Knethen A & Brune B (2007). Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production. FASEB J 21, 2704 2712.
21. Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S & Ichikawa A (1994). Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett 344, 74 78.
22. Kondo K, Machii K, Narita M, Kawamoto A, Yamasaki S & Hamanaka N (1995). ONO-AP-500-02: a non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase. Adv Prostaglandin, Thromboxane, Leukot Res 23, 401 403.
23. Lim H & Dey SK (2000). PPAR δ functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 11, 137 142.
24. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM & Dey SK (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev 13, 1561 1574.
25. Luckhoff A, Pohl U, Mulsch A & Busse R (1988). Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J Pharmacol 95, 189 196.
26. Marasciulo FL, Montagnani M & Potenza MA (2006). Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13, 1655 1665.
27. Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M & Hartl KS et al. (1994). Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2- oxazolyl) ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. Drug Design Discovery 11, 73 89.
28. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D & Wahli W (2001). Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) α and PPARβ mutant mice. J Cell Biol 154, 799 814.
29. Mitchell JA, de Nucci G, Warner TD & Vane JR (1992). Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol 105, 485 489.
30. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR & Warner TD (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20, 2468 2475.
31. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK & Cartwright N (2007). Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J Endocrinol 193, 323 330.
32. Mitchell JA & Warner TD (1999). Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128, 1121 1132.
33. Mitchell JA & Warner TD (2006). COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5, 75 86.
34. Moncada S, Gryglewski R, Bunting S & Vane JR (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663 665.
35. Moncada S & Higgs EA (2006). Nitric oxide and the vascular endothelium. Handb Exp Pharmacol (176 Pt 1 213 254.
36. Moraes LA, Piqueras L & Bishop-Bailey D (2006). Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110, 371 385.
37. Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD & Bishop-Bailey D (2007). Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 109, 3741 3744.
38. Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S & Nakao K (1994). Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90, 1643 1647.
39. Nakayama T (2006). Prostacyclin analogues: prevention of cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 4, 351 359.
40. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M & Samuelsson B (1976). Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261, 558 560.
41. Oliver WR Jr., Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC & Willson TM (2001). A selective peroxisome proliferator- activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98, 5306 5311.
42. Palmer RM, Ashton DS & Moncada S (1988). Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 333, 664 666.
43. Palmer RM, Ferrige AG & Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524 526.
44. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M & Murad F (1991). Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 88, 10480 10484.
45. Pollock JS, Werner F, Mitchell JA & Förstermann U (1993). Characterisation of EDRF/NO synthase as a FAD/FMN containing flavoprotein. Endothelium 1, 147 152.
46. Schwarz UR, Walter U & Eigenthaler M (2001). Taming platelets with cyclic nucleotides. Biochem Pharmacol 62, 1153 1161.
47. Seiler S, Brassard CL, Arnold AJ, Meanwell NA, Fleming JS & Keely SL Jr. (1990). Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 255, 1021 1026.
48. Sessa WC (2004). eNOS at a glance. J Cell Sci 117, 2427 2429.
49. Stitham J, Arehart EJ, Gleim SR, Douville KL & Hwa J (2007). Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat 82, 95 108.
50. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr. & Sternbach DD (2003). Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - synthesis and biological activity. Bioorg Med Chem Lett 13, 1517 1521.
51. Tare M, Parkington HC, Coleman HA, Neild TO & Dusting GJ (1990). Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature 346, 69 71.
52. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K & Masaki T (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411 415.
53. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M & Lazar MA (1995). Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270, 23975 23983.